- Accueil
- Congrès
- JESFC 2023
- Hub 2 08:30:00 Cardiopathies structurelles, intelligence artificielle : l'avenir de...
Cardiopathies structurelles, intelligence artificielle : l'avenir de l'imagerie cardiaque ?
Jeudi
12
Janvier 2023
08:30-09:30
Hub 2
JESFC 2023 |
Présentation flash
Modérateur(s) : Yoan LAVIE-BADIE, Sophie RIBEYROLLES
Orateur(s) : Theo PEZEL, Pamela MOCERI, Antoine LAFONT, Solenn TOUPIN, Camilia HAYOUN, Yoann PRIMET, Marine JULLIEN, Brahim AWARE
08:30
•
Theo Pezel
Additional Prognostic Value of fully-automatic Global Longitudinal Strain using Machine Learning
Voir la présentation
08:35
•
Pamela Moceri
Atrial strain in patients with Pulmonary Arterial Hypertension associated with Congenital Heart Disease
Voir la présentation
08:40
•
Antoine Lafont
Factors associated with high-risk patent foramen ovale in ischemic stroke patients : SAFAS study
Voir la présentation
08:45
•
Solenn Toupin
Incremental prognostic value of fully-automatic LVEF by stress CMR using machine learning
08:50
•
Camilia Hayoun
Incidence, Predictive factors, and Prognostic Impact of Residual Shunt After Percutenous Patent Foramen Ovale Closure
08:55
•
Yoann Primet
Impact of TTVR on Reverse Remodeling of Right-Ventricular function and morphology in patients with severe tricuspid regurgitation – a CMRI pilot study
Voir la présentation
09:00
•
Marine Jullien
Multimodal imaging assessment of prosthetic mitral valve area after transcatheter mitral valve implantation : a three-dimensional echocardiographic and CT scan study
Voir la présentation
09:05
•
Theo Pezel
Incremental prognostic value of fully-automatic machine-learning based global circumferential strain during a stress CMR exam
Voir la présentation
09:10
•
Pamela Moceri
Effect of ASD closure on right ventricular function using 3D Echocardiography
Voir la présentation
09:15
•
Brahim Aware
Prevalence of Pulmonary Hypertension in Severe Aortic Stenosis
09:20
Evaluation of right ventricular dysfunction concomitant to left ventricular dysfunction in cardiotoxicity induced by Trastuzumab in patients followed for HER2+ breast cancer: Experience of the first cardio-oncology unit in Morocco
